NCT05693090 2023-03-06Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerKura Oncology, Inc.Phase 1 Withdrawn
NCT00054470 2012-06-29Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast CancerThe University of Texas Health Science Center at San AntonioPhase 2 Withdrawn